Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.64FDC Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency, growth, and profitability, suggesting a solid foundation and effective management. However, its efficiency and liquidity scores indicate areas needing attention. While revenue and earnings are growing, the company faces challenges in utilizing its assets efficiently and maintaining optimal liquidity levels. The coverage ratio is also mixed, with strong interest coverage but weak equity dividend coverage. Overall, FDC Ltd appears financially stable with good growth prospects, but needs to improve its operational efficiency and liquidity management to enhance its long-term financial health. The recent dividend payout in Mar 2025 could signal a shift in financial strategy, balancing reinvestment with shareholder returns. This analysis provides a balanced view, acknowledging both the strengths and areas for improvement within FDC Ltd's financial profile.
Health Score : 7.64FDC Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency, growth, and profitability, suggesting a solid foundation and effective management. However, its efficiency and liquidity scores indicate areas needing attention. While revenue and earnings are growing, the company faces challenges in utilizing its assets efficiently and maintaining optimal liquidity levels. The coverage ratio is also mixed, with strong interest coverage but weak equity dividend coverage. Overall, FDC Ltd appears financially stable with good growth prospects, but needs to improve its operational efficiency and liquidity management to enhance its long-term financial health. The recent dividend payout in Mar 2025 could signal a shift in financial strategy, balancing reinvestment with shareholder returns. This analysis provides a balanced view, acknowledging both the strengths and areas for improvement within FDC Ltd's financial profile.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
19.00
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
19.29
P/B RATIO
2.18
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
2.46
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
12.09
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹333.6 as on Sep 1, 2026.
Growth Score : 10.00The company's growth trajectory is strong. High revenue, operating profit, EPS, asset, and net income growth rates indicate robust expansion and effective management. The company is successfully growing its revenue and profits, demonstrating a strong market position. This consistent growth is a positive sign of the company's potential for future success. The company's growth rates are excellent.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 14.58 | 16.98 | 8.91 | 8.49 | 2.99 |
| Operating Profit Growth Rate | -23.95 | -1.18 | 35.06 | -4.13 | 6.46 |
| Earnings Per Share (EPS) Growth | -28.18 | -8.74 | 60.26 | -12.59 | 5.49 |
| Asset Growth Rate | 16.05 | 3.22 | 5.34 | 9.97 | 7.55 |
| Net Income Growth Rate | -28.24 | -10.19 | 57.22 | -12.46 | 5.24 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 21 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
FDC Ltd. is a prominent Indian pharmaceutical company established in 1936, specializing in the manufacturing and marketing of a diverse range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. Known for iconic brands like Electral ORS, the company operates across domestic and international markets, focusing on therapeutic areas such as anti-infectives, ophthalmics, and vitamins.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. FDC Ltd's P/E ratio (TTM) is 19.00, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. FDC Ltd's P/B ratio is 2.18, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. FDC Ltd's P/S ratio is 2.46, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. FDC Ltd's PEG ratio is 2.20.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. FDC Ltd's EV/EBITDA ratio is 12.09.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. FDC Ltd's ROE is 11.31%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. FDC Ltd's ROA is 11.85%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. FDC Ltd's ROCE is 17%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. FDC Ltd's operating margin is 15.94%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. FDC Ltd's net margin is 12.94%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. FDC Ltd's current ratio is 1.85.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. FDC Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. FDC Ltd's interest coverage ratio is 76.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. FDC Ltd's DPS is ₹5.01.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. FDC Ltd's EPS is 5.49.
(Source line: "Ratios as of 14 Oct 2026, based on last traded price of ₹333.60. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1936 (as Fairdeal Corporation (Private) Limited)
Headquarters: Mumbai, Maharashtra
Core Offerings: Oral Rehydration Salts (Electral), Anti-infectives (Zifi, Ciprobid), Ophthalmics, Vitamins & Nutraceuticals (Enerzal), Gastrointestinals
Stock Listing: NSE (FDC), BSE (531599)
Promoter: Chandavarkar Family
FDC Ltd. was founded in 1936 by Mr. Anand Chandavarkar and incorporated as Fairdeal Corporation (Private) Limited. Initially engaged in general products, it evolved into a specialized pharmaceutical company. A significant milestone was the introduction of Electral ORS in India, which became a household name. Over decades, FDC expanded its product portfolio into various therapeutic segments and established a strong presence in domestic and international markets, continually investing in R&D and manufacturing capabilities.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| India Formulations | 65% (approx) | Not explicitly disclosed |
| International Business | 25% (approx) | Not explicitly disclosed |
| APIs & Other | 10% (approx) | Not explicitly disclosed |
India Formulations: Focuses on manufacturing and marketing a wide array of branded pharmaceutical products across therapeutic categories such as anti-infectives, ophthalmics, gastrointestinals, and oral rehydration salts (ORS), catering to the domestic market. Key brands include Electral and Zifi.
International Business: Engages in the export of formulations to various countries, primarily in emerging markets, utilizing a network of distributors and local partners. This segment contributes significantly to the company's revenue and global footprint.
APIs & Other: Involves the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) to both internal formulation units and external customers. This segment also includes nutraceuticals and other allied health products.
Mr. Mohan A. Chandavarkar (Chairman & Whole-time Director): An experienced leader steering the company's strategic vision and overall governance for decades. Mr. Nandan M. Chandavarkar (Managing Director & CEO): Leads the executive management, driving operations, business expansion, and day-to-day strategic initiatives.
FDC Inc. (USA)
FDC International Ltd. (UK)
Fairdeal Corporation (Mauritius) Ltd.
Fairdeal Pharma GmbH (Germany)
1:1 Bonus Share issue in November 2022.
The FDC Ltd share price today is ₹333.60 on NSE (FDC), as of 14 Oct 2026.
As of 14 Oct 2026, FDC Ltd share price is ₹333.60, with previous close ₹333.60. Today's range is ₹333.60 to ₹333.60. The 52-week range is ₹312.95 to ₹442.
As of today, FDC Ltd's market cap is ₹5,340.94 crore (Mid Cap).
FDC Ltd's current P/E ratio is 19.00, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.
FDC Ltd's current P/B ratio is 2.18.
FDC Ltd's current dividend yield is 1.50%. Last dividend of ₹3.00 per share was declared on 20-Feb-2024.
FDC Ltd's EPS (TTM) is ₹5.49.
FDC Ltd. is a prominent Indian pharmaceutical company established in 1936, specializing in the manufacturing and marketing of a diverse range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. Known for iconic brands like Electral ORS, the company operates across domestic and international markets, focusing on therapeutic areas such as anti-infectives, ophthalmics, and vitamins.
FDC Ltd is promoted by Chandavarkar Family, holding 69.66% as of 14 Oct 2026.
FDC Ltd is listed on NSE (FDC) and BSE (531599). Its next quarterly results are expected on August 2024.
Capital Expenditures (CapEx)
